Life
Concerns Arise Over FDA's Reduced Use of Advisory Committees
The FDA's decreasing reliance on advisory committees is raising alarms among stakeholders, with potential ramifications for drug approval processes and public discourse.
Editorial Staff
1 min read
The FDA's reported reduction in the use of advisory committees is causing concern among various stakeholders, including drug manufacturers, healthcare providers, and patients.
Advisory committees serve a critical function in facilitating public discourse on drug approvals, and their diminished role may impact the transparency and thoroughness of the approval process.
The implications of this trend could extend to the overall architecture of drug evaluation, potentially affecting the throughput of new therapies entering the market.